

*Disclaimer :*

*The Competition DG makes the information provided by the notifying parties in section 1.2 of Form CO available to the public in order to increase transparency. This information has been prepared by the notifying parties under their sole responsibility, and its content in no way prejudices the view the Commission may take of the planned operation. Nor can the Commission be held responsible for any incorrect or misleading information contained therein.*

**M.7480 – ACTAVIS/ALLERGAN**

**SECTION 1.2**

**Description of the concentration**

1. On November, 17, 2014, Actavis announced its intention to acquire sole control over Allergan (the “Transaction”). The transaction qualifies for review under the EU Merger Regulation.
2. Actavis is an integrated global specialty pharmaceutical company engaged in the development, manufacturing, marketing, sale and distribution of generic, branded generic, brand name, biosimilar and over-the-counter pharmaceutical products. Actavis’s principal executive offices are located in Dublin, Ireland, and it is listed on the New York Stock Exchange (NYSE: ACT).
3. Allergan is a multi-specialty healthcare company with a portfolio of pharmaceuticals, biologics, medical devices and over-the-counter consumer products, with a focus on several medical specialties, including ophthalmology, neurology, medical aesthetics (including breast aesthetics), medical dermatology and urology. Allergan’s corporate headquarters are located in Irvine, California and it is listed on the New York Stock Exchange (NYSE: AGN).